Ivosidenib (AG120)
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 64 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA), Isocitrate Dehydrogenase 1 (IDH1) Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1667
- NCT Identifier
- NCT03471260
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.